Φορτώνει......
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
Although early breast cancer (BC) is highly curable, advanced or metastatic disease poses numerous challenges in terms of medical management and treatment decisions and is associated with significantly worse prognosis. Among the new targeted agents, anticancer drugs exploiting the cell-cycle machine...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Drug Des Devel Ther |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5818877/ https://ncbi.nlm.nih.gov/pubmed/29497278 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S137783 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|